Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer

Study Overview
=================
Brief Summary
-----------------
This pilot research trial studies quantitative imaging metrics derived from contrast enhanced computed tomography (CECT) in enhancing assessment of disease status in patients with kidney cancer. Quantitative imaging is the extraction of quantifiable features from radiological images for the assessment of disease status. Collecting quantitative imaging metrics from CECT imaging may help doctors predict tumor aggressiveness and nuclear grade (tumor stage) and assess treatment response and prognosis in cancer imaging.

Detailed Description
-----------------
PRIMARY OBJECTIVES: I. To investigate the role of quantitative imaging metrics (QIM) as a potential DIAGNOSTIC biomarker. II. To investigate if QIM parameters can differentiate clear cell renal cell carcinoma (RCC) from papillary RCC. III. To evaluate the tumor grade of the target lesion as assessed by QIM from CECT for agreement with the pathological (Fuhrman) grade. IV. To investigate the role of QIM as a potential PROGNOSTIC biomarker. V. To develop a novel method of calculating renal tumor contact surface area (CSA) using advanced image-processing technology (MATLAB®, 3 dimension [D] Synapse) and predict peri-operative variables such as blood loss, operative time and post-operative estimated glomerular filtration rate (eGFR) in patients undergoing partial nephrectomy (PN). VI. To develop QIM that would help in predicting postoperative functional outcomes such as predicted surgically resected volume and postoperative glomerular filtration rate (GFR). OUTLINE: Patients' clinical and imaging data are collected from routine multiphase CECT imaging and used to establish and validate the classification/prediction rule for QIM.

Official Title
-----------------
CT Metrology: Quantitative Imaging Metrics With Advanced Visualization Tools for Cancer Imaging

Conditions
-----------------
Renal Cell Carcinoma

Intervention / Treatment
-----------------
* Other: Medical Chart Review
* Other: Informational Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with a renal mass who are scheduled for surgery for presumed RCC Subjects scheduled for standard of care contrast enhanced CT examination at USC Norris Comprehensive Cancer Center Subjects competent to sign study specific written informed consent Exclusion Criteria: Subjects who are pregnant Subjects who cannot consent for themselves

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational (QIM)<br>Patients' clinical and imaging data are collected from routine multiphase CECT imaging and used to establish and validate the classification/prediction rule for QIM. | Other: Medical Chart Review<br>* Clinical and imaging information collected<br>* Other names: Chart Review;Other: Informational Intervention<br>* Clinical and imaging data collected<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Agreement between QIM predicted and pathologically determined tumor class (clear cell renal cell carcinoma [ccRCC] vs papillary [p]RCC) | Cohen's kappa coefficient will be used to examine the agreement between QIM predicted and pathologically determined tumor class (ccRCC vs. pRCC). | Baseline | 
| Agreement between QIM predicted and pathologically determined tumor (Fuhrman) grade | Examined using weighted kappa coefficient. | Baseline | 
| Agreement between QIM predicted and clinically observed perioperative measurements such as blood loss, operative time, and eGFR | Examined using two-way random single measure with absolute agreement. | Baseline | 
| Agreement between QIM predicted and clinical determined postoperative eGFR | Examined using two-way random single measure with absolute agreement. | Baseline |